Stock Events

OSE Immunotherapeutics 

€6.6
29
+€0.16+2.48% Today

Statistics

Day High
7.2
Day Low
6.56
52W High
-
52W Low
-
Volume
347,114
Avg. Volume
-
Mkt Cap
140.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

21JunExpected
Q4 2020
Q2 2021
Q4 2021
Q2 2022
Q2 2023
Q1 2024
Q1 2024
-0.93
-0.62
-0.31
-0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OSE.PA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol-Myers Squibb is a leading biopharmaceutical company that competes with OSE Immunotherapeutics in the development of immunotherapies for cancer and other diseases.
Merck &
MRK
Mkt Cap318.55B
Merck & Co., Inc. is a global healthcare company that develops immunotherapy treatments for cancer, directly competing with OSE Immunotherapeutics' product pipeline.
Gilead Sciences
GILD
Mkt Cap90.4B
Gilead Sciences, Inc. focuses on the discovery, development, and commercialization of innovative therapeutics in areas including immune-oncology, competing with OSE Immunotherapeutics.
AMGEN
AMGN
Mkt Cap177.72B
Amgen Inc. is a biotechnology company that develops and produces therapeutics in areas including oncology and inflammation, competing with OSE Immunotherapeutics' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap114.81B
Regeneron Pharmaceuticals, Inc. is involved in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions, including cancer immunotherapies, competing with OSE Immunotherapeutics.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca PLC is a global, science-led biopharmaceutical business that develops a range of medicines, including those for cancer immunotherapy, competing with OSE Immunotherapeutics.
Novartis
NVS
Mkt Cap232.42B
Novartis AG is a healthcare company that provides solutions to address the evolving needs of patients worldwide, including in the area of immunotherapy, directly competing with OSE Immunotherapeutics.
Pfizer
PFE
Mkt Cap169.83B
Pfizer Inc. is a global biopharmaceutical company that develops and manufactures healthcare products including vaccines and cancer immunotherapies, competing with OSE Immunotherapeutics.
Roche
RHHBY
Mkt Cap220.72B
Roche Holding AG is a pioneer in healthcare, focusing on pharmaceuticals and diagnostics. It competes with OSE Immunotherapeutics in the development of cancer immunotherapies.
Sanofi
SNY
Mkt Cap128.21B
Sanofi is a global healthcare leader that discovers, develops, and distributes therapeutic solutions. It competes with OSE Immunotherapeutics in the immunotherapy and oncology sectors.

About

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation; CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a novel bispecific checkpoint inhibitor platform that targets PD-1 to fight primary and secondary resistance mechanisms developed by cancers. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
Show more...
CEO
Dr. Dominique Costantini M.D.
Employees
55
Country
FR
ISIN
FR0012127173
WKN
000A14QXP

Listings